1. Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis
- Author
-
Nesrin Ugras, Sibel Kahraman Çetintaş, Gonca Özgün, Gokhan Ocakoglu, Muhammed Sadık Bilgen, Adem Deligonul, Ulviye Yalcinkaya, Uludağ Üniversitesi/Tıp Fakültesi/Cerrahi Patoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Ortopedi Anabilim Dalı., Yalçınkaya, Ulviye, Uğraş, Nesrin, Ocakoğlu, Gökhan, Deligönül, Adem, Çetintaş, Sbel Kahraman, Bilgen, Muhammed Sadık, AAH-5180-2021, AAA-7047-2020, AAH-8924-2021, and AAH-2716-2021
- Subjects
0301 basic medicine ,Male ,Pathology ,Necrosis ,Proliferation ,Adolescents ,Cancer staging ,Metastasis ,0302 clinical medicine ,Enhancer of zeste homologue 2 (EZH2) ,Multicenter ,Middle aged ,Disease free survival ,Children ,Cancer ,Sarcoma, synovial ,Gene expression regulation ,lcsh:R5-920 ,Tumor ,Progression ,Synovial Sarcoma ,Mucin-1 ,EZH2 ,General Medicine ,Prognosis ,Immunohistochemistry ,Synovial sarcoma ,Gene Expression Regulation, Neoplastic ,Retrospective study ,Blood ,Enhancer of zeste homolog 2 protein ,030220 oncology & carcinogenesis ,Soft-tissue ,Ssx-fusion-type ,Female ,Sarcoma ,medicine.symptom ,lcsh:Medicine (General) ,Research Article ,Human ,Risk ,Adult ,medicine.medical_specialty ,Adolescent ,Disease-free survival ,Retrospective analysis ,Neoplasm metastasis ,Research & experimental medicine ,Predictive value ,macromolecular substances ,Prognostic factors ,Biosynthesis ,03 medical and health sciences ,medicine ,Biomarkers, Tumor ,Genetics ,Humans ,Predictive value of tests ,Tumor marker ,Medicine, research & experimental ,Survival analysis ,Neoplastic ,business.industry ,Kaplan-meier estimate ,medicine.disease ,Transcription factor EZH2 ,Retrospective studies ,030104 developmental biology ,Young adult ,Neoplasm staging ,EZH2 protein, human ,Kaplan meier method ,business ,Immunostaining ,Biomarkers - Abstract
Synovial sarcoma (SS) is a type of soft-tissue sarcoma, often linked to poor survival. Although overexpression of enhancer of zeste homologue 2 (EZH2) has been associated with poor prognosis in different tumors, a few studies investigated this link in SS. Here, we analyzed the relationship between EZH2 expression and prognostic factors in SS. We included 29 patients with SS. Immunostaining of EZH2 was performed with (D2C9) XPTM Rabbit mAb antibody, and the results were classified as low EZH2 expression (negative or weak expression) and high EZH2 expression category (moderate or strong expression). Analysis of survival in relation to prognostic factors was performed with Kaplan-Meier survival curves and Cox proportional hazard regression analysis. Our sample included 19/29 female and 10/29 male patients, with age range 16-63 years. The tumor diameter ranged from 2 to 15 cm. Necrosis was observed in 15/29 cases. Sixteen cases had >10 mitoses per 50 high-power fields (HPFs). Out of 29 cases, 14 showed low and 15 had high EZH2 expression. Statistically significant results were obtained for the association between the presence of metastasis and necrosis (p = 0.042), high EZH2 expression and distant metastasis (p = 0.018), high EZH2 expression and necrosis (p = 0.016), and high EZH2 expression and the tumor size >5 cm versus tumor size ≤5 cm (p = 0.014). Patients with all of the following: the tumor size ≤5 cm, low EZH2 expression, and without necrosis and distant metastasis had significantly longer survival time. Our results are consistent with previous studies, suggesting that EZH2 overexpression is an indicator of poor prognosis in SS.
- Published
- 2017